Huntsman Cancer Institute has been an NCI-designated center since 1986. In this application for competitive renewal, we also are seeking designation as a Comprehensive Center. Since the last review, we have made substantial progress: we created programs in Pediatric Cancers, Ovarian Cancer, and Cancer Control and Population Sciences; we added 42 new members from external recruitment including 20 oncologists-- medical, surgical, dermatological, and radiation; we recruited new Chairs of Surgery, Neurosurgery, and Radiation Oncology--all of whom have leadership positions in the Center; we recruited two senior medical oncologists to lead our clinical trials programs; we conducted four investigator-initiated Phase 1 trials; and we initiated an outreach effort across our vast geographical area, with special emphasis on underserved populations in this region--Native Americans, rural residents, and Latinos. In addition, we sharpened the cancer focus of our research programs, which maintain a high level of productivity. Interdisciplinary research interactions are fostered by center- and program-sponsored activities including a seminar series, retreats, and training initiatives, as well as outstanding shared resources. Nearly 30% of our peer-reviewed publications since 1998 reflect inter-programmatic efforts, illustrating a high degree of interdisciplinary coordination and collaboration. In the past funding period, we completed construction on a 230,000 ft(2) building that contains laboratories, offices, an outpatient clinic, clinical research support, and a Cancer Learning Center. We also designed and began construction on a 330,000 ft(2) cancer research hospital (opening in 2004) that will be an extension of the current building. There has been outstanding institutional support for all aspects of our growth, including a new structure in which the Executive Director, Dr. Prescott, reports directly to the President of the University. We plan continued expansion over the next five years, with enduring emphasis on developing disease-site specific research programs to facilitate translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA042014-18
Application #
6919243
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-05-09
Project End
2008-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
18
Fiscal Year
2005
Total Cost
$714,199
Indirect Cost
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Tavtigian, Sean V; Greenblatt, Marc S; Harrison, Steven M et al. (2018) Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med 20:1054-1060
Rogers, R Aaron; Fleming, Aaron M; Burrows, Cynthia J (2018) Unusual Isothermal Hysteresis in DNA i-Motif pH Transitions: A Study of the RAD17 Promoter Sequence. Biophys J 114:1804-1815
Rogers, R Aaron; Fleming, Aaron M; Burrows, Cynthia J (2018) Rapid Screen of Potential i-Motif Forming Sequences in DNA Repair Gene Promoters. ACS Omega 3:9630-9635
Wei, Xiaomu; Calvo-Vidal, M Nieves; Chen, Siwei et al. (2018) Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res 78:2747-2759
Barrott, Jared J; Illum, Benjamin E; Jin, Huifeng et al. (2018) Paracrine osteoprotegerin and ?-catenin stabilization support synovial sarcomagenesis in periosteal cells. J Clin Invest 128:207-218
Sample, Danielle C; Samadder, N Jewel; Pappas, Lisa M et al. (2018) Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients. BMC Gastroenterol 18:115
Delker, Don A; Wood, Austin C; Snow, Angela K et al. (2018) Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia. Cancer Prev Res (Phila) 11:4-15
Madsen, Michael J; Knight, Stacey; Sweeney, Carol et al. (2018) Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at 12q15. Cancer Epidemiol Biomarkers Prev 27:644-652
Trott, Daniel W; Henson, Grant D; Ho, Mi H T et al. (2018) Age-related arterial immune cell infiltration in mice is attenuated by caloric restriction or voluntary exercise. Exp Gerontol 109:99-107
Wu, Yelena P; Parsons, Bridget G; Mooney, Ryan et al. (2018) Barriers and Facilitators to Melanoma Prevention and Control Behaviors Among At-Risk Children. J Community Health 43:993-1001

Showing the most recent 10 out of 1193 publications